|

Á¦¾à¿¡¼ Á¦Á¶µÇ´Â Á¤Á¦´Â ÀϹÝÀûÀ¸·Î ÁÖ¼ººÐÀ» Æ÷ÇÔÇÏ¿© ´Ù¾çÇÑ ÃæÀüÁ¦, °áÇÕÁ¦ ¹× À±È°À¯ µî°ú °°Àº ºÎ¿ø·á·Î ±¸¼ºµÇ¾î ÀÖÀ¸¸ç Á¤Á¦ °úÁ¤¿¡¼ ÁÖ¼ººÐ°ú ´Ù¾çÇÑ ºÎ¿ø·á¸¦ ±ÕÀÏÇÏ°Ô È¥ÇÕÇϱâ À§Çؼ º¹ÀâÇÑ È¥ÇÕ°úÁ¤À» °ÅÄ¡°Ô µË´Ï´Ù.
È¥ÇÕ °øÁ¤¿¡ ´ëÇÑ °ü¸®´Â ÃÖÁ¾ »ý»êµÈ Á¤Á¦ÀÇ Ç°Áú¿¡ ¸Å¿ì Áß¿äÇϸç, ¶ÇÇÑ ÃÖÁ¾ÀûÀ¸·Î È¥ÇÕ ±ÕÀϼº¿¡ ´ëÇØ °ü¸®Çϰí ÅõÀÔ µÈ ¿ø·á ¹°ÁúÀÇ Æ¯¼ºÀ» ºÐ¼®ÇÒ ¼ö ÀÖ½À´Ï´Ù.
Á¦¾à »ý»ê °øÁ¤¿¡ ´ëÇÏ¿© ¹Ì±¹ ½ÄǰÀǾàǰ¾ÈÀüû(USFDA)Àº ¾ö°ÝÇÏ°Ô °ü¸®ÇÑ´Ù. Á¦½ÃµÈ ¼øµµ ±Ô°Ý¿¡ ¸ÂÃß±â À§ÇØ °¢ Batch¸¶´Ù Á¤È®ÇÏ°Ô È¥ÇÕ µÇ´Â °ÍÀÌ ÇÊ¿äÇϸç À̸¦ ÀÚ¼¼ÇÏ°Ô ¾È³»Çϰí ÀÖÀ¸¸ç, È¥ÇÕ °øÁ¤¿¡ ´ëÇÑ Å¸´ç¼º °ËÅ並 À§ÇØ È¥ÇÕµÈ Batch¸¶´Ù ±ÕÀϼº(Homogeneity) °Ë»ç¸¦ Çϰí ÀÖ½À´Ï´Ù.

ÀÌ ¿¬±¸¿¡¼´Â ¶ó¸¸ ºÐ±¤±â(Raman Spectroscopy)¸¦ ÀÌ¿ëÇÏ¿© ÃÖÁ¾ »ý»ê µÈ 3mgÀÇ Á¤Á¦ ³»¿¡¼ ÁÖ¼ººÐÀÎ Naltrexone HCI ¼ººÐÀÇ ÇÔ·®À» Åë°è ó¸® ¹æ½Ä(Chemometric)°ú ºÐ¼®ÀûÀÎ ¹æ¹ýÀ¸·Î ºñ±³ÇÏ¿© ¾Ë¾Æ º¸µµ·Ï ÇϰڽÀ´Ï´Ù.
Table1. Samples
| Sample |
Naltrexone HCI(mg/ tablet) |
|
| 1 |
100% Naltrexone HCI powder |
Feasibility evaluation |
| 2 |
2.70(mg/tablet) powder |
Chemometric model |
| 3 |
2.85(mg/tablet) powder |
| 4 |
3.00(mg/tablet) powder |
| 5 |
3.06(mg/tablet) powder |
| 6 |
3.14(mg/tablet) powder |
| 7 |
3mg T1 |
prediction |
| 8 |
3mg T2 |
785nm laser¿Í Fiber Optic Probe°¡ ÀåÂø µÈ BW TEK»çÀÇ i-Raman Plus Àåºñ°¡ »ç¿ëµÇ¾úÀ¸¸ç ¾ÈÁ¤µÈ »ùÇÃ ÃøÁ¤À» À§Çؼ Probe holder¸¦ °°ÀÌ È°¿ëÇÏ¿´½À´Ï´Ù. 
i-Raman Plus with Fiber optic probe
ºñ´Ò¹é ¾È¿¡ ÀÖ´Â °¢°¢ÀÇ »ùÇõ鿡 ´ëÇØ¼ 3°÷ÀÇ ´Ù¸¥ ºÎºÐÀ» ÃøÁ¤ÇÏ¿´À¸¸ç ¸ðµç »ùÇÃ ÃøÁ¤Àº 300mWÀÇ ·¹ÀÌÀú Ãâ·Â°ú 6ÃÊÀÇ ÃøÁ¤ ½Ã°£À¸·Î ÃøÁ¤µÇ¾ú½À´Ï´Ù.
|